Paul Choi
Stock Analyst at Goldman Sachs
(3.61)
# 802
Out of 4,944 analysts
107
Total ratings
50.72%
Success rate
6.54%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $14.88 | -19.35% | 9 | Jun 25, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $16 → $3 | $19.20 | -84.38% | 4 | May 22, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $7 → $8 | $1.93 | +314.51% | 6 | May 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $5 | $10.38 | -51.83% | 10 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Neutral | $12 → $8 | $6.80 | +17.73% | 3 | May 2, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $60 → $52 | $35.99 | +44.48% | 2 | Apr 17, 2025 | |
| VIR Vir Biotechnology | Maintains: Buy | $28 → $21 | $4.36 | +382.20% | 8 | Apr 17, 2025 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $8.10 | +48.15% | 3 | Apr 17, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Neutral | $4 → $3 | $1.79 | +67.60% | 9 | Apr 17, 2025 | |
| DVAX Dynavax Technologies | Maintains: Sell | $12 → $10 | $10.58 | -5.48% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $196.02 | +14.79% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $143 | $53.90 | +165.31% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $42 | $45.27 | -7.22% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $34.31 | +74.88% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $15.26 | +24.51% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $32.78 | -2.38% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $49.09 | +1.85% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.87 | +290.14% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $400 → $50 | $9.25 | +440.54% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.44 | +1,636.11% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $13.47 | +1,162.06% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $4.87 | +64.27% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $128.89 | +4.74% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $23.60 | +1,171.19% | 2 | Mar 30, 2020 |
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $14.88
Upside: -19.35%
UroGen Pharma
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $19.20
Upside: -84.38%
Gossamer Bio
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $1.93
Upside: +314.51%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $10.38
Upside: -51.83%
Arvinas
May 2, 2025
Maintains: Neutral
Price Target: $12 → $8
Current: $6.80
Upside: +17.73%
Xenon Pharmaceuticals
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $35.99
Upside: +44.48%
Vir Biotechnology
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $4.36
Upside: +382.20%
REGENXBIO
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $8.10
Upside: +48.15%
Esperion Therapeutics
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $1.79
Upside: +67.60%
Dynavax Technologies
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $10.58
Upside: -5.48%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $196.02
Upside: +14.79%
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $53.90
Upside: +165.31%
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $45.27
Upside: -7.22%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $34.31
Upside: +74.88%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $15.26
Upside: +24.51%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $32.78
Upside: -2.38%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $49.09
Upside: +1.85%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.87
Upside: +290.14%
Jun 27, 2023
Maintains: Sell
Price Target: $400 → $50
Current: $9.25
Upside: +440.54%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.44
Upside: +1,636.11%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $13.47
Upside: +1,162.06%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $4.87
Upside: +64.27%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $128.89
Upside: +4.74%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $23.60
Upside: +1,171.19%